Consumption of garlic not associated decreased risk of colorectal cancer
the ONA take:
According to a new study published in World Journal of Gastroenterology, researchers have found that the consumption of raw or cooked garlic or garlic supplements is not significantly linked with a decreased risk for developing colorectal cancer.
For the study, researchers sought to conduct a meta-analysis of trials that prospectively studied the association between garlic or garlic supplement consumption and colorectal cancer. They identidfied five prospective studies that looked at either the consumption of garlic, whether raw or cooked, or garlic supplements and its association with the development of colorectal cancer.
Relative risks with 95% confidence intervals were calculated. Unlike a previous meta-analysis that did identify a significant association between raw or cooked garlic and cancer, this study did not. Researchers found a relative risk of 1.06 (95% CI: 0.95 - 1.19) between consumption of raw or cooked garlic and risk of colorectal cancer.
In addition, the relative risk between garlic supplements and risk of cancer was 1.12 (95% CI: 0.96 - 1.31). Researchers did find, however, non-significant protective benefit of garlic supplements against colorectal cancer in women (RR = 0.84, 95 CI: 0.64 - 1.11), but the opposite effect in men (RR = 1.24; 95% CI: 0.96 - 1.59).
Consumption of raw or cooked garlic or garlic supplements not significantly linked.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|